ALK-Positive Lung Cancer Clinical Trials — 2026 Pipeline Tracker

Active Phase 2 and Phase 3 recruiting trials — ALK-positive NSCLC (March 2026)

The table below reflects recruiting and active trials registered on ClinicalTrials.gov targeting ALK-positive non-small cell lung cancer as of March 2026. DataLookout monitors for new registrations and status changes daily.

Sources: ClinicalTrials.gov. DataLookout monitors for new registrations and status updates daily. Table reflects recruiting and active trials as of March 2026.

ALK rearrangements in NSCLC: a rare but highly druggable target

ALK (anaplastic lymphoma kinase) rearrangements occur in approximately 4–5% of non-small cell lung cancer cases — rarer than EGFR mutations but consistently yielding one of the most treatment-responsive NSCLC subpopulations. The EML4-ALK fusion, formed by an inversion on chromosome 2p, is the dominant rearrangement, present in roughly 90% of ALK-positive cases. Multiple EML4-ALK fusion variants exist (V1 using exon 13, V2 using exon 20, V3 using exon 6), with structural differences that influence oncogenicity and potentially drug resistance.

The ALK+ patient profile is distinctive: younger median age at diagnosis (median 50–52 years versus 65+ for unselected NSCLC), never- or light-smoking history, and predominantly adenocarcinoma histology. ALK+ NSCLC also has one of the highest rates of brain metastases among NSCLC molecular subtypes — over 50% of patients develop CNS disease over the course of their illness — making CNS penetration a critical pharmacological requirement for any ALK inhibitor.

The ALK TKI treatment ladder: crizotinib to lorlatinib

ALK+ NSCLC has undergone three generations of TKI development over approximately 15 years, with each generation improving on activity, CNS penetration, and durability of response:

First generation: crizotinib (now largely obsolete as first-line)

Crizotinib (Xalkori, Pfizer) was the first approved ALK TKI, gaining accelerated FDA approval in 2011. It established the principle that ALK+ NSCLC was TKI-sensitive, with response rates exceeding 60% in previously treated patients. However, crizotinib has limited CNS penetration and patients uniformly develop resistance — most commonly through secondary ALK kinase domain mutations (L1196M, C1156Y, G1269A) or ALK gene amplification. Median PFS was approximately 11 months. Crizotinib has been fully displaced in the first-line setting by superior next-generation agents, though it remains a useful comparator arm in trials involving 2nd-line post-crizotinib settings.

Second generation: alectinib, brigatinib, ceritinib

Second-generation ALK TKIs were designed to overcome crizotinib resistance mutations and improve CNS penetration. Alectinib (Alecensa, Genentech/Roche) and brigatinib (Alunbrig, Takeda) both demonstrated superior PFS versus crizotinib in head-to-head Phase 3 trials (ALEX and ALTA-1L, respectively), becoming the preferred front-line options until lorlatinib data matured. Alectinib showed a median PFS of 34.8 months versus 10.9 months for crizotinib in ALEX (HR 0.43). Brigatinib demonstrated 67% intracranial response rate in patients with baseline brain metastases.

Second-generation agents were active against most first-generation crizotinib resistance mutations but not against the G1202R gatekeeper mutation, which emerged as the dominant mechanism of resistance to 2nd-gen TKIs. Ceritinib is less commonly used due to a less favorable tolerability profile.

Third generation: lorlatinib dominates the front-line

Lorlatinib (Lorbrena, Pfizer) is a macrocyclic ALK/ROS1 TKI with a differentiated structure that enables CNS penetration and activity against all known single ALK resistance mutations, including G1202R. The CROWN Phase 3 trial (NCT03052608) compared lorlatinib versus crizotinib as first-line therapy in ALK+ NSCLC, demonstrating a landmark result: at 5-year follow-up, 60% of lorlatinib patients remained progression-free versus only 8% on crizotinib (HR 0.19, 95% CI 0.13–0.27). This degree of separation makes lorlatinib's CROWN data among the most striking PFS results ever seen in molecularly targeted NSCLC therapy.

Lorlatinib also received approval in the adjuvant setting. The ALINA Phase 3 trial (NCT03456076) compared lorlatinib versus crizotinib following complete resection of stage IB–IIIA ALK+ NSCLC, demonstrating a 73% reduction in recurrence risk (HR 0.27, 95% CI 0.14–0.51). This made lorlatinib the standard adjuvant therapy for resected ALK+ NSCLC, adding a meaningful commercial line beyond metastatic disease.

ALKALI-1 (NCT06765109): neladalkib challenges lorlatinib head-to-head

The most consequential clinical trial in ALK+ NSCLC as of 2026 is ALKALI-1, a global Phase 3 randomized trial run by Nuvalent comparing neladalkib (NVL-655) versus lorlatinib as first-line therapy in TKI-naive ALK-positive NSCLC. It is the first Phase 3 head-to-head trial to directly challenge lorlatinib's dominance — a high-confidence decision by Nuvalent given neladalkib's differentiated preclinical and Phase 1/2 profile.

What is neladalkib and why does it matter?

Neladalkib (NVL-655) is a highly selective, brain-penetrant, macrocyclic ALK inhibitor designed with an explicit structural goal: activity against compound ALK kinase domain mutations that confer lorlatinib resistance. While lorlatinib handles all currently known single ALK mutations, compound mutations — particularly combinations like G1202R+L1196M and G1202R+D1203N — cannot be overcome by any currently approved ALK TKI. These compound mutations are increasingly recognized as the dominant resistance mechanism in post-lorlatinib patients.

In Phase 1/2 data (NovALK-1 expansion cohorts), neladalkib demonstrated a 93% objective response rate in treatment-naive ALK+ NSCLC, with a 100% intracranial response rate in measurable brain metastases — numbers that motivated the Phase 3 investment. More critically, neladalkib showed activity in patients with compound ALK mutations previously treated with lorlatinib, something no approved drug can currently achieve.

The ALKALI-1 trial design and competitive stakes

ALKALI-1 is designed as a superiority trial — not non-inferiority — comparing neladalkib directly versus lorlatinib in TKI-naive patients. The primary endpoint is progression-free survival. If neladalkib demonstrates superior PFS versus lorlatinib in treatment-naive patients, it would displace the current standard of care and potentially establish a new benchmark: a single front-line therapy that not only controls the primary tumor but also preempts the compound mutation resistance that is otherwise inevitable with lorlatinib.

The commercial stakes are substantial. Lorlatinib generated over $1 billion in annual revenue for Pfizer in 2024. A superior front-line alternative would capture a rapidly growing ALK+ market while also potentially addressing the post-lorlatinib unmet need — the same compound mutations that develop after lorlatinib would presumably also emerge (more slowly or differently) after neladalkib, creating a new sequencing question for future trials.

ALTA-3 (NCT03596866): brigatinib vs. alectinib — settling the second-generation debate

ALTA-3 is a Phase 3 head-to-head trial comparing brigatinib (Alunbrig, Takeda) versus alectinib (Alecensa) in patients with ALK+ NSCLC who progressed on crizotinib. While this trial is now of diminishing direct clinical relevance — because lorlatinib's CROWN data has made front-line lorlatinib the preferred strategy over 2nd-gen TKIs — ALTA-3 provides the only prospective randomized data comparing two second-generation agents head-to-head.

The indirect comparison from separate Phase 3 trials (brigatinib ALTA-1L vs. alectinib ALEX) was inconclusive because of differences in trial design, patient populations, and definitions of prior crizotinib treatment. ALTA-3 addresses this gap. The result has implications for patients who began therapy with 2nd-gen agents (particularly in markets where lorlatinib access is limited) and for understanding the comparative CNS activity of the two agents in a controlled setting.

The post-lorlatinib problem: compound mutations and the fourth-generation imperative

With lorlatinib now the preferred front-line therapy, the next clinical challenge is managing disease after lorlatinib progression — a setting with no approved targeted option as of 2026. The dominant mechanism of resistance to lorlatinib in ALK+ NSCLC is compound (double) kinase domain mutations: sequential acquisition of resistance mutations that individually may be surmountable by lorlatinib but in combination are not.

The G1202R "solvent front" mutation at the entrance to the ALK ATP-binding pocket is the pivot point — it emerges commonly with 2nd-gen TKIs and can be overcome by lorlatinib. But when G1202R appears in combination with a second mutation after lorlatinib treatment, no approved drug has activity. This is the mechanistic rationale for neladalkib and for TPX-0131 (BMS), both of which were designed with compound-mutation coverage as a primary objective.

TPX-0131 (NCT04849910): purpose-built for compound mutations

TPX-0131, developed by Turning Point Therapeutics (acquired by Bristol-Myers Squibb in 2022) is a next-generation macrocyclic ALK/ROS1 inhibitor in Phase 1/2 testing that specifically targets compound ALK kinase domain mutations. Unlike neladalkib, which is also being developed in the treatment-naive setting, TPX-0131's clinical program has focused on the post-lorlatinib population — patients who have progressed on all available ALK TKIs and have no approved targeted options.

Phase 1 dose-escalation data from NCT04849910 have shown responses in patients with compound ALK mutations post-lorlatinib — a setting where no prior investigational drug had demonstrated consistent clinical activity. The Phase 2 expansion is evaluating activity across different compound mutation pairs. If TPX-0131 achieves durable responses in this population, it would represent the first targeted therapy for the post-lorlatinib unmet need, an important standalone commercial opportunity independent of first-line positioning.

Brain metastases: the clinical standard in ALK+ NSCLC drug development

ALK+ NSCLC has one of the highest CNS metastasis rates in all of solid oncology. Across clinical trial populations, 30–40% of patients have brain metastases at first diagnosis; the cumulative incidence over the course of treatment exceeds 50%. This means CNS penetration is not a secondary consideration for ALK TKI development — it is a primary efficacy criterion.

Lorlatinib's CNS activity is one of its strongest clinical differentiators. In CROWN, the intracranial objective response rate for patients with baseline measurable CNS metastases was 82% — nearly double the 23% seen with crizotinib. Among patients without baseline CNS metastases, CNS progression events were dramatically reduced on lorlatinib (0% at 12 months) versus crizotinib (15% at 12 months), suggesting that lorlatinib may prevent CNS seeding in addition to treating established brain disease.

Any drug that attempts to improve on lorlatinib in the front-line setting — including neladalkib in ALKALI-1 — will need to demonstrate non-inferior or superior CNS activity. This is a high bar, and CNS outcomes are likely to be a key secondary or co-primary endpoint in Phase 3 trials.

ALK+ NSCLC vs. ROS1-fusion NSCLC: overlapping TKI landscape

ROS1 fusions occur in approximately 1–2% of NSCLC and share significant structural homology with ALK at the kinase domain level. This homology means that many ALK TKIs also have ROS1 activity — crizotinib, lorlatinib, and neladalkib are all dual ALK/ROS1 inhibitors. This creates an interesting clinical situation: drugs developed primarily for ALK+ NSCLC may also receive approval for ROS1+ NSCLC, and vice versa.

Nuvalent's ALKALI-1 trial title refers to ALK+ patients, but neladalkib's Phase 1/2 data includes ROS1+ expansion cohorts. The SOLAR-1 trial (NVL-520, Nuvalent's dedicated ROS1 inhibitor) is a separate program. Competitive intelligence teams tracking ALK+ NSCLC should monitor both programs simultaneously, as they represent coordinated market coverage of the ALK/ROS1 kinase overlap.

Related clinical trials and monitoring resources

ALK-positive NSCLC is part of the broader targeted therapy revolution in lung cancer. DataLookout monitors related areas including:

• NSCLC clinical trials — full non-small cell lung cancer pipeline, all mutation subgroups
• EGFR mutant lung cancer clinical trials — the largest NSCLC molecular subgroup by volume, with parallel TKI evolution
• KRAS G12C clinical trials — the third large NSCLC targeted oncology market; KRAS and ALK mutations are mutually exclusive
• Small cell lung cancer clinical trials — distinct biology, but ALK+ NSCLC can rarely transform to SCLC as a resistance mechanism

Frequently asked questions

What is ALK-positive lung cancer?

ALK-positive lung cancer is non-small cell lung cancer (NSCLC) harboring a chromosomal rearrangement of the ALK gene, most commonly the EML4-ALK fusion. It accounts for approximately 4–5% of NSCLC cases. ALK+ NSCLC disproportionately affects younger patients (median age ~50) and never- or light-smokers, and has a high rate of brain metastases. Multiple EML4-ALK fusion variants (V1, V3, others) exist with different biological properties. The fusion constitutively activates ALK kinase signaling, driving tumor growth — and making ALK a highly tractable drug target, with three generations of approved TKIs and a fourth in development.

What is the current standard treatment for ALK-positive NSCLC?

Lorlatinib (Lorbrena, Pfizer) is the global standard of care for first-line treatment of ALK-positive NSCLC as of 2026. The CROWN Phase 3 trial demonstrated 5-year PFS of 60% versus 8% for crizotinib (HR 0.19) — one of the largest treatment effect sizes ever observed in molecularly targeted lung cancer therapy. Lorlatinib is also approved in the adjuvant post-resection setting based on the ALINA trial (HR 0.27 for disease recurrence). The ALKALI-1 Phase 3 trial is now testing neladalkib (NVL-655) as a potential lorlatinib successor in the first-line setting.

What happens after lorlatinib progression in ALK-positive NSCLC?

Post-lorlatinib resistance is the major unmet need in ALK+ NSCLC. The dominant mechanism is compound (double) ALK kinase domain mutations — combinations like G1202R+L1196M that cannot be overcome by any currently approved TKI. No targeted standard of care exists post-lorlatinib; options include platinum-based chemotherapy and clinical trial enrollment. Fourth-generation ALK TKIs — neladalkib (Nuvalent) and TPX-0131 (BMS, NCT04849910) — are in Phase 1/2 and Phase 3 development specifically targeting compound mutations. These represent the only investigational agents with demonstrated clinical activity in this setting.

What is the ALKALI-1 trial?

ALKALI-1 (NCT06765109) is a global Phase 3 trial by Nuvalent comparing neladalkib (NVL-655) versus lorlatinib in treatment-naive ALK+ NSCLC. Neladalkib is a highly selective, brain-penetrant, macrocyclic ALK/ROS1 inhibitor designed to overcome compound ALK resistance mutations while delivering superior or comparable efficacy to lorlatinib in TKI-naive patients. Phase 1/2 data showed 93% ORR in treatment-naive ALK+ and 100% intracranial ORR in measurable brain metastases. If ALKALI-1 meets its primary endpoint (superior PFS), it would represent the first successful head-to-head challenge to lorlatinib and displace the current standard of care.

How can I track new ALK-positive lung cancer trials?

DataLookout monitors ClinicalTrials.gov daily and sends filtered email digests for ALK-positive NSCLC. Configure alerts for "ALK rearrangement", "ALK inhibitor", "EML4-ALK", "lorlatinib", "neladalkib", or specific NCT IDs. The free plan covers one profile with weekly alerts; Starter ($49/month) provides daily alerts and up to five profiles; Pro ($149/month) offers unlimited profiles. Setup takes under five minutes at datalookout.com.